Securities code: Shanghai Haoyuan Chemexpress Co.Ltd(688131) securities abbreviation: Shanghai Haoyuan Chemexpress Co.Ltd(688131) Announcement No.: 2022026 Shanghai Haoyuan Chemexpress Co.Ltd(688131)
Notice on issuing shares and paying cash to purchase assets and raising supporting funds and general risk warning of related party transactions
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Shanghai Haoyuan Chemexpress Co.Ltd(688131) (hereinafter referred to as “the company”) intends to purchase 100% equity of YaoYuan Pharmaceutical Chemistry (Shanghai) Co., Ltd. by issuing shares and paying cash, and issue shares to Shanghai Anshu Information Technology Co., Ltd., the controlling shareholder, to raise supporting funds (hereinafter referred to as “the transaction”).
Upon the application of the company, the trading of the company’s shares has been suspended since the opening of the market on February 21, 2022. During the suspension period, the company timely performs the obligation of information disclosure according to relevant regulations. For details, see the company’s website published on the Shanghai Stock Exchange (www.sse. Com. CN.) Announcement of Shanghai Haoyuan Chemexpress Co.Ltd(688131) on planning to issue shares and pay cash to purchase assets and raise supporting funds (Announcement No.: 2022020) and announcement of Shanghai Haoyuan Chemexpress Co.Ltd(688131) on planning to issue shares and pay cash to purchase assets and raise supporting funds (Announcement No.: 2022022).
On March 3, 2022, the fourth meeting of the third board of directors of the company deliberated and approved the proposal on the company’s issuance of shares and payment of cash to purchase assets and raise supporting funds and related party transactions and other proposals related to this transaction. For details, see the company’s website of Shanghai Stock exchange (www.sse. Com. CN.) on March 5, 2022 And the plan for Shanghai Haoyuan Chemexpress Co.Ltd(688131) issuing shares and paying cash to purchase assets and raising supporting funds and related party transactions and relevant announcements of the designated information disclosure media.
According to relevant regulations, upon the application of the company to Shanghai Stock Exchange, the trading of the company’s shares will resume from the opening of the market on March 7, 2022. Since the audit and evaluation of assets involved in this transaction have not been completed, the board of directors of the company decided not to hold the general meeting of shareholders to consider this transaction. After the completion of relevant audit and evaluation, the company will reconvene the board of directors to review the relevant matters of this transaction. The specific scheme shall be subject to the restructuring report reviewed and announced by the company’s reconvened board of directors.
According to the guidance on the supervision of listed companies No. 7 on the supervision of abnormal stock transactions related to major asset restructuring of listed companies issued by the CSRC, if there are obvious abnormalities in stock transactions before the first announcement of the company’s transaction, there may be a risk that the transaction will be suspended and terminated due to the filing and investigation of suspected insider trading.
The approval procedures for this transaction include but are not limited to:
1. After the audit and evaluation report of this transaction is issued, the company reconvenes the board of directors to review and approve this transaction plan;
2. The general meeting of shareholders of the company deliberated and approved the transaction plan;
3. This transaction needs to be reviewed by Shanghai Stock Exchange and registered with China Securities Regulatory Commission.
The above approval items have not been completed, and there are uncertainties about whether the transaction scheme can obtain relevant approval and the time of obtaining relevant approval. Therefore, there is uncertainty about whether the transaction can be successfully implemented. Investors are reminded of the above risks.
It is hereby announced.
Shanghai Haoyuan Chemexpress Co.Ltd(688131) board of directors March 5, 2022
